Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

23.50 -0.57 (-2.39%)
Streaming Delayed Price Updated: 12:04 PM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Recap: Ultragenyx Pharmaceutical Q2 Earnings ↗
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Ultragenyx Shares Tumble On Initial Efficacy Missing Expectations, This Analyst Sees 'Viable Path Forward" ↗
 
Via Benzinga
News headline image
Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher ↗
U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
  
Via Benzinga
News headline image
Ultragenyx's Neurogenetic Disorder Candidate Shows Favorable Tolerability, Clinical Activity ↗
 
Via Benzinga
News headline image
Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 28, 2022 ↗
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter. 
Via Benzinga
News headline image
Expert Ratings for Ultragenyx Pharmaceutical ↗
Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years ↗
 
Via Benzinga
News headline image
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday ↗
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and... 
Via Benzinga
News headline image
Dow Surges 500 Points; Johnson & Johnson Lowers Guidance ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday. 
Via Benzinga
News headline image
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue... 
Via Benzinga
News headline image
Why U.S. Stocks Are Trading Higher; Housing Starts Drop Further In June ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 350 points on Tuesday. 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap of Monday's Biotech Catalysts - End of the Day Summary ↗
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: 
Via Benzinga
News headline image
Netflix To $210? Here's The Biggest Price Target Changes For Friday ↗
Piper Sandler cut The Goldman Sachs Group, Inc. (NYSE: GS) price target from $430 to $410. Goldman Sachs shares fell 0.1% to $296.79 in pre-market trading. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More ↗
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
News headline image
Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know ↗
Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00. Shares of Ultragenyx Pharmaceutical are trading up 2.9%... 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Ultragenyx Pharmaceutical's Earnings Outlook ↗
Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022 ↗
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to... 
Via Benzinga
News headline image
Where Ultragenyx Pharmaceutical Stands With Analysts ↗
Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
News headline image
Ultragenyx Pharmaceutical: Q4 Earnings Insights ↗
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.